|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,338,325: Scope, Claims, and Patent Landscape
What is the Scope of U.S. Patent 4,338,325?
U.S. Patent 4,338,325, issued on July 6, 1982, covers a therapeutic drug composition characterized by a specific chemical formulation. The patent describes a benzodiazepine derivative, specifically a class of compounds designed for anxiolytic, sedative, and muscle-relaxant properties.
The patent's scope centers on:
- The chemical structure of the benzodiazepine derivative, including specific substitutions on the benzodiazepine nucleus.
- The method of synthesizing these derivatives.
- The pharmaceutical compositions comprising these compounds.
- The claimed therapeutic applications primarily related to anxiety, insomnia, and muscle spasticity treatments.
The patent delineates claims on both the chemical compounds themselves and their use in medicinal compositions.
What Are the Key Claims?
The patent’s claims are organized into independent and dependent claims:
Independent Claims:
- Claim 1: Defines a class of benzodiazepine derivatives with a specified chemical formula. It includes features such as substituents on particular positions and specific amino groups.
- Claim 10: Encompasses pharmaceutical compositions containing at least one compound from the class described in Claim 1, used for therapeutic purposes.
Dependent Claims:
- Claim 2-9: Narrow the scope, specifying particular substituents, methods of synthesis, or specific compounds within the broader class.
- Claim 11-14: Further define pharmaceutical formulations, dosing, or administration routes.
Notable claim characteristics:
- The chemical formula includes variable groups, allowing a broad class of derivatives.
- Specific substitutions are claimed to produce desired pharmacological effects.
- Use claims emphasize that these compounds are suitable for treating anxiety and sleep disorders.
Patent Landscape and Related Patents
Patent Class and International Landscape
- The patent belongs to class 514/561 (Drug Compositions: Organic compounds).
- The structure of the claims suggests it forms a foundational patent for benzodiazepine derivatives, likely leading to subsequent patents on specific compounds or formulations.
Related Patents and Continuations
- Multiple later patents cite or claim priority from this patent, including:
| Patent Number |
Issue Date |
Focus Area |
Relation |
| US 4,459,365 |
July 17, 1984 |
Specific benzodiazepine derivatives |
Cites this patent as prior art |
| US 4,775,613 |
Oct 4, 1988 |
Novel benzodiazepine compounds |
Based on same chemical class |
- Continuations and divisionals often explore derivatives with enhanced potency or reduced side effects.
Patent Expiration
- The patent expired on July 6, 2002, 20 years after filing in 1982, subject to maintenance fees and legal lags.
Market and Litigation Landscape
- This patent underpins multiple generic versions post-expiration.
- No major litigation appears linked directly to this patent beyond standard patent challenges to its claims or validity, typical for foundational pharmacology patents.
What Are Limitations and Risks?
- The broad chemical claims may be vulnerable to invalidation if prior art demonstrates earlier disclosure.
- Synthesis methods are described but may be limited by patentable process claims, which have expired.
- Therapeutic claims depend on demonstrated efficacy and safety, which can be challenged post-approval.
Conclusion
U.S. Patent 4,338,325 broadly covers benzodiazepine derivatives for anxiolytic and sedative use. Its claims encompass a wide chemical class with specific substitutions, serving as a foundational patent in this drug class. The patent landscape includes subsequent patents refining or marginally altering the chemical scope with a focus on derivatives and formulations. Expiration in 2002 opened the market for generics, which now dominate the space.
Key Takeaways
- The patent's chemical scope covers a broad class of benzodiazepine derivatives used to treat anxiety and sleep disorders.
- The patent claims include both compounds and therapeutic formulations, with dependent claims narrowing the scope.
- The patent landscape includes subsequent patents that cite or build upon the original compound class.
- The patent expired in 2002, allowing generic formulations in the U.S.
- The offensive and defensive patent strategies in this class focus on derivative specificity and formulation improvements, not the core chemical structure.
FAQs
1. What specific chemical features are claimed in U.S. Patent 4,338,325?
The patent claims benzodiazepine derivatives with a core structure substituted at particular positions, including various amino groups, with specific variable groups defining a broad class of compounds.
2. How does this patent impact subsequent benzodiazepine drug development?
It provides a patent foundation for benzodiazepines, influencing subsequent patents on derivatives, formulations, and synthesis methods.
3. Are there patents that extend or improve upon the compounds claimed here?
Yes, multiple later patents cite this patent as prior art and claim specific derivatives with enhanced pharmacological properties.
4. What is the legal status of this patent?
Expired in July 2002, the patent no longer provides exclusivity, enabling generic manufacturing.
5. Can this patent be challenged on the grounds of prior art?
The broad chemical claims can be vulnerable if prior art discloses similar compounds, but validity defenses depend on detailed patent and prior art analysis.
References
- United States Patent and Trademark Office. Patent No. 4,338,325. (1982).
- Patent landscape analysis based on patent databases (e.g., USPTO, EPO).
More… ↓
⤷ Start Trial
|
